[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [@andrewcaravello](/creator/twitter/andrewcaravello) "Thanks for putting together this graphic @ApptillionAI its really helpful in showing how similar the M7 protocol and the $NWBO #DCVax method are. Just one small but important fix: under Step X the DCVax side currently says it uses -CSF and IL-4 (missing a word and unclear). To be precise it should say either: GM-CSF and IL-4 (Kalinski DC1 method licensed by NWBO) or GM-CSF alone (original DCVax-L patent) 🔬 Importantly this isnt speculation the 2020 Mayo Clinic paper by Parney & Dietz makes it clear that M7 evolved directly from a cytokine/TLR3-based maturation sequence (M5) and that its"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1946198095026430177) 2025-07-18 13:19:19 UTC 1070 followers, XXX engagements "$NWBO 🛸 The Signal That Was Jammed by $MRK (Part Deux) How Three Dendritic Cell Trials in Colorectal Cancer Were Silenced (Until They Werent) 🗞 Why I Deleted the Original Post On July X I deleted the first version of this post originally titled The Signal That Was Jammed. It was based on a promising but misdirected listing (NCT03735290) that pointed to a different terminated study a basket trial using an allogeneic dendritic cell vaccine with checkpoint inhibitors in cold tumors like gastric and gastroesophageal junctional adenocarcinomas. It wasnt the Roswell colorectal trial I was looking"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1943273438153433431) 2025-07-10 11:37:46 UTC 1068 followers, 3063 engagements "To Whom It May Concern Im not here to argue with trolls. Im here because this matters. $NWBO matters Im a board certified emergency and internal medicine physician. Ive worked countless night shifts helping people through their worst moments then spent my days building something of my own. That something is a wellness and weight loss clinic I opened under the Medi-Weightloss brand. Within a year I was asked to serve as Vice President of the Medi-Weightloss National Advisory Committee due to the consistently strong clinical outcomes at my clinic. While I no longer hold that role I remain an"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1942466564231406036) 2025-07-08 06:11:32 UTC 1071 followers, 9520 engagements "If the July XX NICE letter is accurate then MHRA approval of DCVax-L has already occurred in substance. Here is why: NICE says $NWBO is still fully occupied and engaged in the MAA process with MHRA But NICE also says NWBO is not yet in a position to submit evidence for guidance That is not a contradiction. It is standard UK protocol. MHRA comes first. NICE follows. NICE cannot begin its full assessment until MHRA finalizes the label the Summary of Product Characteristics (SmPC). So if NWBO is unable to submit it is because MHRA is still finalizing that label. And that only happens after the"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1945181384911544766) 2025-07-15 17:59:16 UTC 1069 followers, 4067 engagements "🔬 The Convergence Corridor How a Foundational Discovery and the $NWBO - $AZN Immune Alliance Could Reshape Oncology 🧠 TL;DR (89 min read) Dr. Dmitry Gabrilovichs pioneering research revealed how tumors sabotage dendritic cells the bodys immune teachers and showed how these cells could be rescued reprogrammed and redeployed. Years later NWBO operationalized this vision with DCVax-L a personalized vaccine made from a patients own tumor lysate and dendritic cells clinically proven to extend survival in glioblastoma. What followed was a quiet strengthening of the platform: enhanced GMP"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1944964911227965901) 2025-07-15 03:39:05 UTC 1069 followers, 1938 engagements "🧱 DCVax-L Is the Baselayer: Why $NWBO Now Has Leverage Over the Entire Immunotherapy Stack Dr. Carolyn Britten a dendritic cell vaccine expert and former colleague of Dr. Linda Liau (principal investigator of DCVax-Ls Phase X trial) and Dr. Antoni Ribas (a global authority on immunotherapy combinations) has joined BeiGene as VP of Clinical Development for Solid Tumors. On the surface its a strong hire. But dig deeperand it signals something far more strategic. Top immuno-oncology companies are racing to build modular stacks to attack solid tumors. But none of it functions properly without a"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1930287187511132179) 2025-06-04 15:35:03 UTC 1070 followers, 4453 engagements "This could be a new record for $NWBO with an XXXXX% short ratio. How is this level of short interest permitted or even possible without manipulation @DOGE_SEC @SECGov @CohenMilstein"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1945786828721660041) 2025-07-17 10:05:05 UTC 1070 followers, 5364 engagements "📄 Why the July XX NICE Letter Strongly Suggests $NWBO Is in the Final Step: Labeling A step-by-step breakdown for those trying to decode the regulatory silence Lets walk through what the July XX NICE letter actually says what it doesnt say and why all roads point to one conclusion: MHRA labeling is happening right now. X What the Letter Says NWBO is still fully occupied and engaged in the Marketing Authorisation Application (MAA) process with the MHRA. The company is not yet in a position to provide their evidence submission This tells us two things: ✔ NWBO is still in active dialogue with"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1945222957535551496) 2025-07-15 20:44:28 UTC 1070 followers, 2077 engagements "When the $NWBO immune education platform was approaching clinical maturity $AZN brought in Dr. Dmitry Gabrilovich in May 2018. He had spent decades studying how tumors suppress dendritic cells and how they could be functionally restored precisely the biology DCVax-L was designed to address That same year AstraZeneca shifted direction. It expanded its focus beyond checkpoint inhibitors and began investing in intratumoral stimulation TLR agonists like MEDI9197 and translational efforts targeting myeloid dysfunction and local immune activation. The timing matched Gabrilovichs arrival and"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1945094785250762967) 2025-07-15 12:15:09 UTC 1068 followers, XXX engagements "🔍 If the July XX NICE Letter Is Real Then MHRA Approval Is Functionally Complete Heres the Step-by-Step Explanation: ⚠ This analysis assumes the July XX 2025 letter from NICE is genuine and accurately reflects $NWBO current status in the UK regulatory process. As per the actual NICE submission manual. That document makes one thing clear beyond all doubt: The statement from NICE that NWBO is not yet in a position to submit does not signal delay or failure. It is exactly what we would expect at the very end of the regulatory process during the labeling phase. 📄 Direct link to the NICE"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1945184497411956827) 2025-07-15 18:11:38 UTC 1070 followers, 3976 engagements "$NWBO 🧠 Why the XX Billion Dollar Merck and Daiichi Deal Might Be Just the Beginning of Something Much Larger: #DCVax In 2023 Merck paid XX billion dollars to co-develop three antibody drug conjugates from Daiichi Sankyo. That included X billion upfront XXX billion in options and the rest tied to milestones. The message was clear. Merck was assembling a next-generation cancer stack. But despite its size that deal did not include the most important layer the adaptive immune intelligence that tells you what to target in the first place. That layer is DCVax. 🎯 What ADCs Are Designed to Do and"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1939407838914220049) 2025-06-29 19:37:15 UTC 1071 followers, 5258 engagements "The CXCR4 Firewall: The Hidden Keystone in $NWBO Immunotherapy Fortress Introduction This narrative builds on an insight first noted over a decade ago by @maveric92283613 who flagged the CXCR4 maneuver when few others were paying attention. What follows is not only a reconstruction of that moment but a full elaboration of its structural and scientific relevance in the landscape we now face. In the world of immunooncology most breakthroughs are announced through headlines and press releases. But some of the most consequential movesthose that define a platforms foundationhappen quietly. In 2012"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1944268525276676208) 2025-07-13 05:31:53 UTC 1069 followers, 4397 engagements "🔬 The M7 Reflection: How Mayos Protocol Quietly Validated $NWBO s DCVax Immune Platform What Looked Like Innovation Was Actually Confirmation Section 1: What Is the M7 Protocol The M7 protocol is Mayo Clinics most advanced and effective method for generating mature immunostimulatory dendritic cells (DCs) from glioblastoma (GBM) patient monocytes. It was developed after empirically testing seven different culture conditions (M1 through M7) to solve a critical problem: monocytes from GBM patients are often immunosuppressed and tend to yield immature or dysfunctional DCs when standard methods"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1945935233662030060) 2025-07-17 19:54:48 UTC 1070 followers, 3926 engagements "$NWBO 📦 Whats Left Probably Just the Label And Thats Not a Small Thing When youre tracking the progress of an advanced therapy like #DCVax-L its tempting to think in binary terms: is it approved yet or not But when you get to the very end of a regulatory review especially for a personalized cell therapy the question isnt just if its approved. Its: what exactly are we approving And what does that mean in real world terms Thats where labeling comes in. Lets unpack it. 🧾 What Is a Drug Label Really In regulatory language the label isnt just the sticker on the box. Its the entire approved"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1942276432400372111) 2025-07-07 17:36:01 UTC 1070 followers, 3371 engagements "$NWBO Can the July 2025 Review Be Cited as Evidence for DCVax-L 🧠📄✅ Yes once this review is formally published (even as a preprint as it is now) it becomes a citable academic source in the scientific and clinical community. This is a meaningful shift. 📚🔬 What this means: Prior to this: People could cite the original JAMA Oncology 2022 publication on the DCVax-L trial but they could not cite any independent academic source that placed DCVax-L side by side with other standard immunotherapies such as checkpoint inhibitors or TTFields in a formal clinical review or comparison framework. ❌📉"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1944765471095427263) 2025-07-14 14:26:34 UTC 1069 followers, 2616 engagements "🧠 Three Plays One Platform: Yorkvilles Modular Immune Stack Across NWBO Indaptus and SkinJect 🪶TLDR ( 1215 min read): Between Dec 2024 and Feb 2025 Yorkville funded $NWBO (DCVax + Eden) $INDP (DECOY10/20) and $MDCX (SkinJect microneedle patch). Viewed together the deals form a modular immunotherapy stack: signal ignition therapeutic execution and skin-based delivery programmable and real-world deployable under SI XX. SkinJect is in Phase X and has shown clean dermal penetration with cytotoxic payloads. It is compatible with all Bosch Matrix boosters except live virus (V937). DECOY20 already"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1945174785849237725) 2025-07-15 17:33:03 UTC 1070 followers, 6770 engagements "$NWBO 🧬 DCVax for Narcissism A Thought Experiment on Immune Calibration and Self-Obsession Narcissism is not classified as an immune disorder but maybe it should be. At its core narcissism is the pathological over-recognition of the self. It is a psychological state where the internal signal of me is amplified beyond all proportion often at the expense of empathy regulation or external truth. Now consider what dendritic cells do. Dendritic cells are immune instructors. Their job is to distinguish self from non-self and to train the immune system to respond appropriately. They maintain"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1946221903770943870) 2025-07-18 14:53:55 UTC 1070 followers, 2160 engagements "$NWBO 🧠 The Quiet Engine: How #DCVax Became the Core of a Coordinated Immunotherapy Infrastructure 📘 Foreword For years the narrative around Northwest Biotherapeutics and its dendritic cell vaccine (DCVax-L) has been treated as a high-risk high-promise biotech story: a small company with world-class science fighting for legitimacy in a market dominated by pharma giants. But a different picture is now coming into focus one that challenges the premise of isolation and instead suggests a quiet deliberate coordination behind the scenes. What if DCVax is not simply a therapy in development but a"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1941976496215912455) 2025-07-06 21:44:11 UTC 1065 followers, 3595 engagements "$NWBO 🧠 Part X of 2: The Silent Stack How Mayo Quietly Reproduced the DCVax Immune Engine Trial by Trial 🪶TL;DR 🕰 Estimated Read Time: 2730 minutes 🎗 #GlioblastomaAwarenessDay The Silent Stack explores how Mayo Clinic has effectively validated Northwest Biotherapeutics DCVax immune platform without ever naming it. Through a series of independently executed trials using pooled tumor lysate and matured dendritic cells Mayo reproduced the precise immune architecture survival outcomes and tumor-agnostic versatility long associated with DCVax. Dr. Marnix Boschs 2025 Matrix outlines how the"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1945505349844316627) 2025-07-16 15:26:35 UTC 1070 followers, 6534 engagements "🧠Strategic Convergence: Yorkville $NWBO Indaptus and Modular Immune Architecture 📡 TL;DR (22-25 min read): Yorkvilles dual financing of NWBO and $INDP reveals a deeper strategy: the rise of a programmable immunotherapy system. #DCVax DECOY20 and Eden form the core of an adaptive platform that integrates danger signals viral ignition and synthetic TLR boosters. Not a drug; a system. Not a company; a platform. In early 2025 Yorkville Advisors (YA II PN Ltd.) executed two sequential financing agreements: X. A $X million convertible note with Northwest Biotherapeutics announced on February 13"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1944682317563277584) 2025-07-14 08:56:09 UTC 1070 followers, 7796 engagements "Right here in $NWBO official ASCO 2019 press release its stated explicitly: The brain metastases trial has been designed together with the Mayo Clinic and will be conducted there. NWBO Press Release June X 2019 Thats not a citation. Thats public confirmation of formal collaboration on trial design and execution. Not observational. Not retroactive. Mayo is actively building the next generation of DCVax-Direct with NWBO. So when we say Mayo quietly validated the immune engine this proves its not just validation anymore. Its co-development. Appreciate you @AdvanceGradert flagging this. Absolute"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1945837369934143685) 2025-07-17 13:25:55 UTC 1070 followers, 1884 engagements "The Therapy Dr. Makary Just Described Already Exists $NWBO Scott the trials for this method are not in progress. They are not waiting for funding or early development. They are already complete. In fact they have been completed across multiple cancers. At Mayo Clinic this method has already been tested in glioblastoma metastatic melanoma recurrent ovarian cancer and follicular lymphoma. Each time it followed the same blueprint. Blood is drawn monocytes are isolated dendritic cells are matured outside the body pulsed with tumor antigens then reinfused to activate the immune system. There was"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1945909182655279332) 2025-07-17 18:11:17 UTC 1069 followers, XXX engagements "🧬 $NWBO DCVax: The Platform That Owns the Mechanism 🕰 Est. Read Time: 2832 min 📌 TL;DR The Core in One Read DCVax is not just a vax its a programmable immune system. Built on autologous DCs pooled tumor lysate and plug-in TLR-based boosters it delivers personalized instruction without requiring pt-specific tumor samples. The DC maturation protocol developed by Dr. Kalinski (Roswell) and now exclusively licensed to NWBO has already been validated in real pts across GBM (Mayo) and melanoma (JITC 2021). TBVA logic drives tumor-agnostic targeting with the Bosch Matrix enabling immune"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1945835929865736342) 2025-07-17 13:20:12 UTC 1070 followers, 3712 engagements "$NWBO DCVax-L Gains First Ever Recognition in the Academic Oncology Framework for Glioblastoma 🧠💉📊 A July 2025 radiotherapy review authored by oncology experts from Spain marks a material shift in how #DCVax-L is positioned within the treatment discourse for glioblastoma. For the first time a peer facing academic publication has included DCVax-L in a structured immunotherapy comparison table alongside checkpoint inhibitors oncolytic viruses vaccine platforms and cytokine based therapies. The table presents phase III data with median overall survival of XXXX months in recurrent GBM (rGBM"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1944763287830163757) 2025-07-14 14:17:54 UTC 1070 followers, 4674 engagements "🩸How $NWBO Integrated Platelet Biology Dendritic Cell Licensing and a Silent Immune Engine Estimated Reading Time: 1012 minutes 🧪 TL;DR: The Engine Behind the Silence Mill Creeks PLTMax produces pooled tumor lysate rich in vascular antigens. Mayo proved the lysate works when combined with dendritic cells prepared using Northwest Biotherapeutics method. The trial succeeded without naming the company but the immune engine was theirs. Mill Creek owns the reagent. Mayo confirmed the system. Northwest Biotherapeutics owns the method. Flaskworks automates it. SI XX enables delivery. The trial"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1946078002950873340) 2025-07-18 05:22:06 UTC 1070 followers, 3726 engagements "$NWBO 🧠 DCVax-Direct the Mayo Trials and $MRK Multimillion Dollar Validation of This Platform 🧬 The Mechanism: What DCVax-Direct Actually Does DCVax-Direct relies on a time-tested immunological sequence. 1.Unloaded dendritic cells are injected directly into the tumor 2.They absorb tumor antigens on site 3.They mature migrate to lymph nodes 4.They present tumor-associated peptides via MHC to T cells 5.This triggers systemic immune activation Its a smart immune relay the tumor provides the signal the dendritic cell translates it and the immune system learns to attack. This isnt new theory."  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1942951852875624828) 2025-07-09 14:19:54 UTC 1069 followers, 3443 engagements "Heres a clean factual breakdown of why $NWBO controls the entire autologous dendritic cell platform (legally scientifically and commercially) All sources are verifiable. 🕰 Estimated read time: 10-12 min Intellectual Property Ownership of Autologous Dendritic Cell Methods for Cancer Immunotherapy Overview: The immunotherapeutic method involving autologous dendritic cells (DCs) pulsed ex vivo with tumor lysate is a clinically tested approach protected by intellectual property (IP) rights. Critically the tumor lysate itself whether autologous or pooled allogeneic is not patentable as it is a"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1944109981717967106) 2025-07-12 19:01:54 UTC 1069 followers, 6038 engagements "$NWBO 🧪 From Transition States to Drug Design: The Original Spark In classical chemistry the transition state is the fleeting high-energy configuration a molecule passes through when converting from reactant to product. It is the point of maximum instability where bonds are neither fully broken nor fully formed. In drug discovery chemists realized that if you could build a molecule that mimics this precise shape and energy distribution you could trick an enzyme into binding it with high affinity often more strongly than its actual substrate. This realization led to the development of the"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1942566998510051486) 2025-07-08 12:50:38 UTC 1070 followers, 32.5K engagements "Great question and you are right to sense that this sits somewhere between $NWBO DCVax-L and Direct in format. In the Mayo trial they used autologous dendritic cells meaning each patients own immune cells were collected via leukapheresis. But instead of harvesting tumor tissue from each patient like in DCVax-L they pulsed those dendritic cells with a pooled tumor lysate library made from surgically resected glioblastoma tumors donated by other patients. That lysate was processed under GMP conditions into a standardized cryopreserved product. It was almost certainly manufactured and stored by"  [@andrewcaravello](/creator/x/andrewcaravello) on [X](/post/tweet/1945899271615815705) 2025-07-17 17:31:54 UTC 1070 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@andrewcaravello
"Thanks for putting together this graphic @ApptillionAI its really helpful in showing how similar the M7 protocol and the $NWBO #DCVax method are. Just one small but important fix: under Step X the DCVax side currently says it uses -CSF and IL-4 (missing a word and unclear). To be precise it should say either: GM-CSF and IL-4 (Kalinski DC1 method licensed by NWBO) or GM-CSF alone (original DCVax-L patent) 🔬 Importantly this isnt speculation the 2020 Mayo Clinic paper by Parney & Dietz makes it clear that M7 evolved directly from a cytokine/TLR3-based maturation sequence (M5) and that its"
@andrewcaravello on X 2025-07-18 13:19:19 UTC 1070 followers, XXX engagements
"$NWBO 🛸 The Signal That Was Jammed by $MRK (Part Deux) How Three Dendritic Cell Trials in Colorectal Cancer Were Silenced (Until They Werent) 🗞 Why I Deleted the Original Post On July X I deleted the first version of this post originally titled The Signal That Was Jammed. It was based on a promising but misdirected listing (NCT03735290) that pointed to a different terminated study a basket trial using an allogeneic dendritic cell vaccine with checkpoint inhibitors in cold tumors like gastric and gastroesophageal junctional adenocarcinomas. It wasnt the Roswell colorectal trial I was looking" @andrewcaravello on X 2025-07-10 11:37:46 UTC 1068 followers, 3063 engagements
"To Whom It May Concern Im not here to argue with trolls. Im here because this matters. $NWBO matters Im a board certified emergency and internal medicine physician. Ive worked countless night shifts helping people through their worst moments then spent my days building something of my own. That something is a wellness and weight loss clinic I opened under the Medi-Weightloss brand. Within a year I was asked to serve as Vice President of the Medi-Weightloss National Advisory Committee due to the consistently strong clinical outcomes at my clinic. While I no longer hold that role I remain an" @andrewcaravello on X 2025-07-08 06:11:32 UTC 1071 followers, 9520 engagements
"If the July XX NICE letter is accurate then MHRA approval of DCVax-L has already occurred in substance. Here is why: NICE says $NWBO is still fully occupied and engaged in the MAA process with MHRA But NICE also says NWBO is not yet in a position to submit evidence for guidance That is not a contradiction. It is standard UK protocol. MHRA comes first. NICE follows. NICE cannot begin its full assessment until MHRA finalizes the label the Summary of Product Characteristics (SmPC). So if NWBO is unable to submit it is because MHRA is still finalizing that label. And that only happens after the" @andrewcaravello on X 2025-07-15 17:59:16 UTC 1069 followers, 4067 engagements
"🔬 The Convergence Corridor How a Foundational Discovery and the $NWBO - $AZN Immune Alliance Could Reshape Oncology 🧠 TL;DR (89 min read) Dr. Dmitry Gabrilovichs pioneering research revealed how tumors sabotage dendritic cells the bodys immune teachers and showed how these cells could be rescued reprogrammed and redeployed. Years later NWBO operationalized this vision with DCVax-L a personalized vaccine made from a patients own tumor lysate and dendritic cells clinically proven to extend survival in glioblastoma. What followed was a quiet strengthening of the platform: enhanced GMP" @andrewcaravello on X 2025-07-15 03:39:05 UTC 1069 followers, 1938 engagements
"🧱 DCVax-L Is the Baselayer: Why $NWBO Now Has Leverage Over the Entire Immunotherapy Stack Dr. Carolyn Britten a dendritic cell vaccine expert and former colleague of Dr. Linda Liau (principal investigator of DCVax-Ls Phase X trial) and Dr. Antoni Ribas (a global authority on immunotherapy combinations) has joined BeiGene as VP of Clinical Development for Solid Tumors. On the surface its a strong hire. But dig deeperand it signals something far more strategic. Top immuno-oncology companies are racing to build modular stacks to attack solid tumors. But none of it functions properly without a" @andrewcaravello on X 2025-06-04 15:35:03 UTC 1070 followers, 4453 engagements
"This could be a new record for $NWBO with an XXXXX% short ratio. How is this level of short interest permitted or even possible without manipulation @DOGE_SEC @SECGov @CohenMilstein" @andrewcaravello on X 2025-07-17 10:05:05 UTC 1070 followers, 5364 engagements
"📄 Why the July XX NICE Letter Strongly Suggests $NWBO Is in the Final Step: Labeling A step-by-step breakdown for those trying to decode the regulatory silence Lets walk through what the July XX NICE letter actually says what it doesnt say and why all roads point to one conclusion: MHRA labeling is happening right now. X What the Letter Says NWBO is still fully occupied and engaged in the Marketing Authorisation Application (MAA) process with the MHRA. The company is not yet in a position to provide their evidence submission This tells us two things: ✔ NWBO is still in active dialogue with" @andrewcaravello on X 2025-07-15 20:44:28 UTC 1070 followers, 2077 engagements
"When the $NWBO immune education platform was approaching clinical maturity $AZN brought in Dr. Dmitry Gabrilovich in May 2018. He had spent decades studying how tumors suppress dendritic cells and how they could be functionally restored precisely the biology DCVax-L was designed to address That same year AstraZeneca shifted direction. It expanded its focus beyond checkpoint inhibitors and began investing in intratumoral stimulation TLR agonists like MEDI9197 and translational efforts targeting myeloid dysfunction and local immune activation. The timing matched Gabrilovichs arrival and" @andrewcaravello on X 2025-07-15 12:15:09 UTC 1068 followers, XXX engagements
"🔍 If the July XX NICE Letter Is Real Then MHRA Approval Is Functionally Complete Heres the Step-by-Step Explanation: ⚠ This analysis assumes the July XX 2025 letter from NICE is genuine and accurately reflects $NWBO current status in the UK regulatory process. As per the actual NICE submission manual. That document makes one thing clear beyond all doubt: The statement from NICE that NWBO is not yet in a position to submit does not signal delay or failure. It is exactly what we would expect at the very end of the regulatory process during the labeling phase. 📄 Direct link to the NICE" @andrewcaravello on X 2025-07-15 18:11:38 UTC 1070 followers, 3976 engagements
"$NWBO 🧠 Why the XX Billion Dollar Merck and Daiichi Deal Might Be Just the Beginning of Something Much Larger: #DCVax In 2023 Merck paid XX billion dollars to co-develop three antibody drug conjugates from Daiichi Sankyo. That included X billion upfront XXX billion in options and the rest tied to milestones. The message was clear. Merck was assembling a next-generation cancer stack. But despite its size that deal did not include the most important layer the adaptive immune intelligence that tells you what to target in the first place. That layer is DCVax. 🎯 What ADCs Are Designed to Do and" @andrewcaravello on X 2025-06-29 19:37:15 UTC 1071 followers, 5258 engagements
"The CXCR4 Firewall: The Hidden Keystone in $NWBO Immunotherapy Fortress Introduction This narrative builds on an insight first noted over a decade ago by @maveric92283613 who flagged the CXCR4 maneuver when few others were paying attention. What follows is not only a reconstruction of that moment but a full elaboration of its structural and scientific relevance in the landscape we now face. In the world of immunooncology most breakthroughs are announced through headlines and press releases. But some of the most consequential movesthose that define a platforms foundationhappen quietly. In 2012" @andrewcaravello on X 2025-07-13 05:31:53 UTC 1069 followers, 4397 engagements
"🔬 The M7 Reflection: How Mayos Protocol Quietly Validated $NWBO s DCVax Immune Platform What Looked Like Innovation Was Actually Confirmation Section 1: What Is the M7 Protocol The M7 protocol is Mayo Clinics most advanced and effective method for generating mature immunostimulatory dendritic cells (DCs) from glioblastoma (GBM) patient monocytes. It was developed after empirically testing seven different culture conditions (M1 through M7) to solve a critical problem: monocytes from GBM patients are often immunosuppressed and tend to yield immature or dysfunctional DCs when standard methods" @andrewcaravello on X 2025-07-17 19:54:48 UTC 1070 followers, 3926 engagements
"$NWBO 📦 Whats Left Probably Just the Label And Thats Not a Small Thing When youre tracking the progress of an advanced therapy like #DCVax-L its tempting to think in binary terms: is it approved yet or not But when you get to the very end of a regulatory review especially for a personalized cell therapy the question isnt just if its approved. Its: what exactly are we approving And what does that mean in real world terms Thats where labeling comes in. Lets unpack it. 🧾 What Is a Drug Label Really In regulatory language the label isnt just the sticker on the box. Its the entire approved" @andrewcaravello on X 2025-07-07 17:36:01 UTC 1070 followers, 3371 engagements
"$NWBO Can the July 2025 Review Be Cited as Evidence for DCVax-L 🧠📄✅ Yes once this review is formally published (even as a preprint as it is now) it becomes a citable academic source in the scientific and clinical community. This is a meaningful shift. 📚🔬 What this means: Prior to this: People could cite the original JAMA Oncology 2022 publication on the DCVax-L trial but they could not cite any independent academic source that placed DCVax-L side by side with other standard immunotherapies such as checkpoint inhibitors or TTFields in a formal clinical review or comparison framework. ❌📉" @andrewcaravello on X 2025-07-14 14:26:34 UTC 1069 followers, 2616 engagements
"🧠 Three Plays One Platform: Yorkvilles Modular Immune Stack Across NWBO Indaptus and SkinJect 🪶TLDR ( 1215 min read): Between Dec 2024 and Feb 2025 Yorkville funded $NWBO (DCVax + Eden) $INDP (DECOY10/20) and $MDCX (SkinJect microneedle patch). Viewed together the deals form a modular immunotherapy stack: signal ignition therapeutic execution and skin-based delivery programmable and real-world deployable under SI XX. SkinJect is in Phase X and has shown clean dermal penetration with cytotoxic payloads. It is compatible with all Bosch Matrix boosters except live virus (V937). DECOY20 already" @andrewcaravello on X 2025-07-15 17:33:03 UTC 1070 followers, 6770 engagements
"$NWBO 🧬 DCVax for Narcissism A Thought Experiment on Immune Calibration and Self-Obsession Narcissism is not classified as an immune disorder but maybe it should be. At its core narcissism is the pathological over-recognition of the self. It is a psychological state where the internal signal of me is amplified beyond all proportion often at the expense of empathy regulation or external truth. Now consider what dendritic cells do. Dendritic cells are immune instructors. Their job is to distinguish self from non-self and to train the immune system to respond appropriately. They maintain" @andrewcaravello on X 2025-07-18 14:53:55 UTC 1070 followers, 2160 engagements
"$NWBO 🧠 The Quiet Engine: How #DCVax Became the Core of a Coordinated Immunotherapy Infrastructure 📘 Foreword For years the narrative around Northwest Biotherapeutics and its dendritic cell vaccine (DCVax-L) has been treated as a high-risk high-promise biotech story: a small company with world-class science fighting for legitimacy in a market dominated by pharma giants. But a different picture is now coming into focus one that challenges the premise of isolation and instead suggests a quiet deliberate coordination behind the scenes. What if DCVax is not simply a therapy in development but a" @andrewcaravello on X 2025-07-06 21:44:11 UTC 1065 followers, 3595 engagements
"$NWBO 🧠 Part X of 2: The Silent Stack How Mayo Quietly Reproduced the DCVax Immune Engine Trial by Trial 🪶TL;DR 🕰 Estimated Read Time: 2730 minutes 🎗 #GlioblastomaAwarenessDay The Silent Stack explores how Mayo Clinic has effectively validated Northwest Biotherapeutics DCVax immune platform without ever naming it. Through a series of independently executed trials using pooled tumor lysate and matured dendritic cells Mayo reproduced the precise immune architecture survival outcomes and tumor-agnostic versatility long associated with DCVax. Dr. Marnix Boschs 2025 Matrix outlines how the" @andrewcaravello on X 2025-07-16 15:26:35 UTC 1070 followers, 6534 engagements
"🧠Strategic Convergence: Yorkville $NWBO Indaptus and Modular Immune Architecture 📡 TL;DR (22-25 min read): Yorkvilles dual financing of NWBO and $INDP reveals a deeper strategy: the rise of a programmable immunotherapy system. #DCVax DECOY20 and Eden form the core of an adaptive platform that integrates danger signals viral ignition and synthetic TLR boosters. Not a drug; a system. Not a company; a platform. In early 2025 Yorkville Advisors (YA II PN Ltd.) executed two sequential financing agreements: X. A $X million convertible note with Northwest Biotherapeutics announced on February 13" @andrewcaravello on X 2025-07-14 08:56:09 UTC 1070 followers, 7796 engagements
"Right here in $NWBO official ASCO 2019 press release its stated explicitly: The brain metastases trial has been designed together with the Mayo Clinic and will be conducted there. NWBO Press Release June X 2019 Thats not a citation. Thats public confirmation of formal collaboration on trial design and execution. Not observational. Not retroactive. Mayo is actively building the next generation of DCVax-Direct with NWBO. So when we say Mayo quietly validated the immune engine this proves its not just validation anymore. Its co-development. Appreciate you @AdvanceGradert flagging this. Absolute" @andrewcaravello on X 2025-07-17 13:25:55 UTC 1070 followers, 1884 engagements
"The Therapy Dr. Makary Just Described Already Exists $NWBO Scott the trials for this method are not in progress. They are not waiting for funding or early development. They are already complete. In fact they have been completed across multiple cancers. At Mayo Clinic this method has already been tested in glioblastoma metastatic melanoma recurrent ovarian cancer and follicular lymphoma. Each time it followed the same blueprint. Blood is drawn monocytes are isolated dendritic cells are matured outside the body pulsed with tumor antigens then reinfused to activate the immune system. There was" @andrewcaravello on X 2025-07-17 18:11:17 UTC 1069 followers, XXX engagements
"🧬 $NWBO DCVax: The Platform That Owns the Mechanism 🕰 Est. Read Time: 2832 min 📌 TL;DR The Core in One Read DCVax is not just a vax its a programmable immune system. Built on autologous DCs pooled tumor lysate and plug-in TLR-based boosters it delivers personalized instruction without requiring pt-specific tumor samples. The DC maturation protocol developed by Dr. Kalinski (Roswell) and now exclusively licensed to NWBO has already been validated in real pts across GBM (Mayo) and melanoma (JITC 2021). TBVA logic drives tumor-agnostic targeting with the Bosch Matrix enabling immune" @andrewcaravello on X 2025-07-17 13:20:12 UTC 1070 followers, 3712 engagements
"$NWBO DCVax-L Gains First Ever Recognition in the Academic Oncology Framework for Glioblastoma 🧠💉📊 A July 2025 radiotherapy review authored by oncology experts from Spain marks a material shift in how #DCVax-L is positioned within the treatment discourse for glioblastoma. For the first time a peer facing academic publication has included DCVax-L in a structured immunotherapy comparison table alongside checkpoint inhibitors oncolytic viruses vaccine platforms and cytokine based therapies. The table presents phase III data with median overall survival of XXXX months in recurrent GBM (rGBM" @andrewcaravello on X 2025-07-14 14:17:54 UTC 1070 followers, 4674 engagements
"🩸How $NWBO Integrated Platelet Biology Dendritic Cell Licensing and a Silent Immune Engine Estimated Reading Time: 1012 minutes 🧪 TL;DR: The Engine Behind the Silence Mill Creeks PLTMax produces pooled tumor lysate rich in vascular antigens. Mayo proved the lysate works when combined with dendritic cells prepared using Northwest Biotherapeutics method. The trial succeeded without naming the company but the immune engine was theirs. Mill Creek owns the reagent. Mayo confirmed the system. Northwest Biotherapeutics owns the method. Flaskworks automates it. SI XX enables delivery. The trial" @andrewcaravello on X 2025-07-18 05:22:06 UTC 1070 followers, 3726 engagements
"$NWBO 🧠 DCVax-Direct the Mayo Trials and $MRK Multimillion Dollar Validation of This Platform 🧬 The Mechanism: What DCVax-Direct Actually Does DCVax-Direct relies on a time-tested immunological sequence. 1.Unloaded dendritic cells are injected directly into the tumor 2.They absorb tumor antigens on site 3.They mature migrate to lymph nodes 4.They present tumor-associated peptides via MHC to T cells 5.This triggers systemic immune activation Its a smart immune relay the tumor provides the signal the dendritic cell translates it and the immune system learns to attack. This isnt new theory." @andrewcaravello on X 2025-07-09 14:19:54 UTC 1069 followers, 3443 engagements
"Heres a clean factual breakdown of why $NWBO controls the entire autologous dendritic cell platform (legally scientifically and commercially) All sources are verifiable. 🕰 Estimated read time: 10-12 min Intellectual Property Ownership of Autologous Dendritic Cell Methods for Cancer Immunotherapy Overview: The immunotherapeutic method involving autologous dendritic cells (DCs) pulsed ex vivo with tumor lysate is a clinically tested approach protected by intellectual property (IP) rights. Critically the tumor lysate itself whether autologous or pooled allogeneic is not patentable as it is a" @andrewcaravello on X 2025-07-12 19:01:54 UTC 1069 followers, 6038 engagements
"$NWBO 🧪 From Transition States to Drug Design: The Original Spark In classical chemistry the transition state is the fleeting high-energy configuration a molecule passes through when converting from reactant to product. It is the point of maximum instability where bonds are neither fully broken nor fully formed. In drug discovery chemists realized that if you could build a molecule that mimics this precise shape and energy distribution you could trick an enzyme into binding it with high affinity often more strongly than its actual substrate. This realization led to the development of the" @andrewcaravello on X 2025-07-08 12:50:38 UTC 1070 followers, 32.5K engagements
"Great question and you are right to sense that this sits somewhere between $NWBO DCVax-L and Direct in format. In the Mayo trial they used autologous dendritic cells meaning each patients own immune cells were collected via leukapheresis. But instead of harvesting tumor tissue from each patient like in DCVax-L they pulsed those dendritic cells with a pooled tumor lysate library made from surgically resected glioblastoma tumors donated by other patients. That lysate was processed under GMP conditions into a standardized cryopreserved product. It was almost certainly manufactured and stored by" @andrewcaravello on X 2025-07-17 17:31:54 UTC 1070 followers, XXX engagements